JMJ PHARMA
ActiveSummary
JMJ PHARMA has been active since 2021 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €111,605 and a net result of €1,900. Equity is growing by about 4.8% per year across the filed financial years. Its solvency ranks better than 24% of 12,678 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 1.3% (low).
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
08-06
NBB filing
Annual accounts filed
financial year 2025 · abbreviated format
2025
29-07
NBB filing
Annual accounts filed
financial year 2024 · full format
2024
31-12
Financial
Equity above €100,000equity €109,706 ▲14.7%
2 profitable years in a row build equity to €109,706.
11-06
NBB filing
Annual accounts filed
financial year 2023 · micro format
2023
31-12
Financial
Back to profitnet €8,869
Net result €8,869 after one loss-making year.
02-06
NBB filing
Annual accounts filed
financial year 2022 · micro format
2022
31-12
Financial
Weakest financial yearnet -€34,788
Net result drops to -€34,788, the lowest in the series; recovery starts the following year.
29-06
NBB filing
Annual accounts filed
financial year 2021 · micro format
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
0 of 1 deed read
About the unread acts
We know of 1 Belgian Official Gazette act for this company. It has not been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.